Spero Therapeutics (FRA:2HA) Change In Inventory : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Spero Therapeutics Change In Inventory?

Spero Therapeutics's change in inventory for the quarter that ended in Sep. 2024 was €0.00 Mil. It means Spero Therapeutics's inventory stayed the same from Jun. 2024 to Sep. 2024 .

Spero Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Spero Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Spero Therapeutics's Total Inventories for the quarter that ended in Sep. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Spero Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.00.

Spero Therapeutics Change In Inventory Historical Data

The historical data trend for Spero Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Change In Inventory Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Spero Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Spero Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Spero Therapeutics (FRA:2HA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Spero Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Spero Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Spero Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	7.045
	=	0.00

Spero Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

SPRO:USA 2HA:Germany

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines